NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeoGenomics reports robust Q4 earnings, targets profitability in 2023

NeoGenomics delivered strong financial performance in Q4 2022 and full-year 2022, with a focus on sustainable long-term growth. The company aims to achieve adjusted EBITDA positive by Q4 2023 through strategic initiatives, including revenue growth, margin improvement, and operational efficiencies.

NeoGenomics reports robust Q1 results, eyes growth in diagnostics

NeoGenomics' Q1 performance reflects strong revenue growth and operational improvements, driven by strategic priorities and salesforce optimization.
While facing challenges in market share capture and modalities impact, the company's focus on automation and revenue cycle management presents growth opportunities.
Overall, NeoGenomics is well-positioned to achieve its full-year guidance and capitalize on opportunities in advanced diagnostics and revenue optimization.

NeoGenomics excels in Q2, raises guidance on strong growth prospects

NeoGenomics delivered strong financial results, raised revenue guidance, and improved operational efficiencies. With a focus on NGS portfolio expansion, revenue growth, and strategic planning, the company is well-positioned for future success amidst market challenges.

NeoGenomics reports strong Q3 growth, eyes accelerated breast coverage

NeoGenomics demonstrated robust growth and operational improvements in Q3.
The company's focus on high-value areas like breast cancer is a strategic advantage.
Challenges include potential delays in submissions and ongoing labor inflation concerns.
Opportunities lie in accelerated breast coverage, sales force expansion, and payment efficiency enhancements.

NeoGenomics reports strong Q4 earnings and outlines growth strategies

NeoGenomics delivered strong financial performance in Q4 2023, with revenue growth, improved profitability, and a focus on strategic investments for future growth and operational efficiency.
The company's strengths lie in its strategic focus areas, commitment to value creation, and solid financial position, positioning it well for sustainable success and market leadership.
While facing challenges such as market dynamics and operational hurdles, NeoGenomics has opportunities in expanding market share, product innovation, and strategic partnerships to drive growth and profitability.
Overall, NeoGenomics' performance, strengths, challenges, and opportunities indicate a resilient business poised for continued growth, profitability, and market expansion in the evolving healthcare landscape.

NeoGenomics reports robust Q1 growth, eyes M&A and innovation

NeoGenomics delivered strong financial performance in Q1 2024, driven by revenue growth and operational improvements.
The company's strategic priorities, leadership enhancements, and regulatory outlook bode well for future growth and innovation.
While facing challenges in legal defense and market dynamics, NeoGenomics is well-positioned to leverage opportunities in M&A, product launches, and commercial expansion.

NeoGenomics reports robust Q2 growth amidst legal challenges

NeoGenomics delivered strong financial performance in Q2 2024, with revenue growth, positive adjusted EBITDA, and raised revenue guidance for the year.
The company's strategic focus on innovation, operational efficiency, and growth positions it well to capitalize on the evolving healthcare landscape and increasing demand for advanced diagnostics.
While facing legal challenges, NeoGenomics is actively exploring solutions and remains committed to driving value creation and expanding its market presence through product development and strategic initiatives.

NeoGenomics reports record Q3 earnings, eyes growth through innovation

NeoGenomics delivered strong financial performance in Q3 2024, with record revenues and improved adjusted EBITDA, driven by NGS growth.
The company's strategic focus on sustainable growth, innovation, and financial management strengths position it well for future success.
Challenges lie in addressing profitability evolution, successful Neo Helix integration, and balancing short-term impact with long-term value creation.
Opportunities include Neo Helix development, revenue mix diversification, and achieving the revised adjusted EBITDA guidance range.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc., announced two promotions within its senior leadership team, effective immediately.

NeoGenomics Announces Senior Leadership Promotions

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its first quarter 2024 financial results on Tuesday, April 30, 2024.

NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data at AACR, showing its commitment to advancing cancer patient care through innovative research & development initiatives.

NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting

NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy

The consensus price target hints at a 43.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics released its 2023 ESG Report, measuring key sustainability focus areas – quality, integrity, accountability, teamwork, and innovation.

NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. will participate in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, Mass.

NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference

The consensus price target hints at a 29.6% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know

NeoGenomics (NASDAQ: NEO) stock price popped sharply this week after the company published strong financial results. It soared to a high of $16.50, its highest point since December 29th.

NeoGenomics stock surged but technicals point to a pullback

While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

NeoGenomics (NEO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

NeoGenomics, Inc (NEO) Q4 2023 Earnings Call Transcript

NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.06 per share a year ago.

NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. today announced fourth quarter and full year 2023 results for the period ended December 31, 2023.

NeoGenomics Reports Fourth Quarter and Full Year 2023 Results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has signed the Working with Cancer Pledge to support team members living with or caring for a loved one with cancer.

NeoGenomics Signs Working with Cancer Pledge in Support of Employees

NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc., will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024.

NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024

NeoGenomics ( NEO ) is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer.

Bull of the Day: NeoGenomics (NEO)

Light & Wonder Inc

Wix.com

NEO, WIX and LNW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 9, 2024.

Best Momentum Stocks to Buy for January 9th

RBB Bancorp

Toyota Motor

NEO, WIX, LNW, TM and RBB have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.

New Strong Buy Stocks for January 9th

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of NeoGenomics, Inc. (NASDAQ: NEO) resulting from allegations that NeoGenomics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased NeoGenomics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrange.

ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco and will present on Monday, Jan. 8, 8:15 p.m. ET.

NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a subsidiary of NeoGenomics Inc., will appeal the preliminary injunction issued by the United States District Court for the Middle District of North Carolina. The initial determination is that Natera, Inc. demonstrated a likelihood that products using RaDaR technology infringe one Natera, Inc. patent.

NeoGenomics to Appeal Ruling

FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual San Antonio Breast Cancer Symposium (SABCS). RaDaR data will be presented during a Poster Spotlight Session featuring an updated analysis of the TRACER study, which assessed patients with early-stage breast cancer across multiple subtypes and the potential utility of using RaDaR in this setting, including for baseline detection, for monitoring therapy response in the neoadjuvant setting, and for post-operative recurrence monitoring.

NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response

FT. MYERS, FL / ACCESSWIRE / November 14, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New York City. Members of NeoGenomics' management team will participate in a fireside chat on Wednesday, November 29th at 9:00 a.m.

News for NeoGenomics Stock (NEO)